iVIEW Therapeutics was awarded SBIR Innovative grant by NIH’s National Eye Institute

Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative start-up specialty pharmaceutical company focusing on topical drug and medical device development, today announced that it has received a Small Business Innovation Research (SBIR) Award from National Eye Institute(NEI) at National Institutes of Health (NIH). The phase I SBIR grant is awarded to iVIEW’s project titled ” Novel Extended Release Povidone Iodine Ophthalmic Drop for Viral Conjunctivitis”. “This award is a NEI’s recognition of iVIEW’s innovative approach to solve this unmet medical need — viral conjunctivitis”, Dr. Bo Liang, Founder & Director at iVIEW comments, “we will progress quickly though pre-clinical studies and move into proof-of-concept human trials with the innovative extended release formulation of Povidone Iodine ophthalmic drops for viral conjunctivitis.” Dr. John J. Baldwin, Co-founder and Director of iVIEW, further commented, “This work is a further extention of the Founders long term interest in novel treatments for ocular diseases through improving the profile of established medicaments using extended release strategies”

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2019 iVIEW Therapeutics, Inc. All rights reserved.